Literature DB >> 22460713

Chemokine-like receptor 1 regulates skeletal muscle cell myogenesis.

Mark E Issa1, Shanmugam Muruganandan, Matthew C Ernst, Sebastian D Parlee, Brian A Zabel, Eugene C Butcher, Christopher J Sinal, Kerry B Goralski.   

Abstract

The chemokine-like receptor-1 (CMKLR1) is a G protein-coupled receptor that is activated by chemerin, a secreted plasma leukocyte attractant and adipokine. Previous studies identified that CMKLR1 is expressed in skeletal muscle in a stage-specific fashion during embryogenesis and in adult mice; however, its function in skeletal muscle remains unclear. Based on the established function of CMKLR1 in cell migration and differentiation, we investigated the hypothesis that CMKLR1 regulates the differentiation of myoblasts into myotubes. In C(2)C(12) mouse myoblasts, CMKLR1 expression increased threefold with differentiation into multinucleated myotubes. Decreasing CMKLR1 expression by adenoviral-delivered small-hairpin RNA (shRNA) impaired the differentiation of C(2)C(12) myoblasts into mature myotubes and reduced the mRNA expression of myogenic regulatory factors myogenin and MyoD while increasing Myf5 and Mrf4. At embryonic day 12.5 (E12.5), CMKLR1 knockout (CMKLR1(-/-)) mice appeared developmentally delayed and displayed significantly lower wet weights and a considerably diminished myotomal component of somites as revealed by immunolocalization of myosin heavy chain protein compared with wild-type (CMKLR1(+/+)) mouse embryos. These changes were associated with increased Myf5 and decreased MyoD protein expression in the somites of E12.5 CMKLR1(-/-) mouse embryos. Adult male CMKLR1(-/-) mice had significantly reduced bone-free lean mass and weighed less than the CMKLR1(+/+) mice. We conclude that CMKLR1 is essential for myogenic differentiation of C(2)C(12) cells in vitro, and the CMKLR1 null mice have a subtle skeletal muscle deficit beginning from embryonic life that persists during postnatal life.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460713      PMCID: PMC3378017          DOI: 10.1152/ajpcell.00187.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  41 in total

Review 1.  The molecular regulation of myogenesis.

Authors:  L A Sabourin; M A Rudnicki
Journal:  Clin Genet       Date:  2000-01       Impact factor: 4.438

2.  Involvement of myogenic regulator factors during fusion in the cell line C2C12.

Authors:  Stéphane Dedieu; Germain Mazères; Patrick Cottin; Jean-Jacques Brustis
Journal:  Int J Dev Biol       Date:  2002-03       Impact factor: 2.203

3.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

4.  Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis.

Authors:  Shanmugam Muruganandan; Sebastian D Parlee; Jillian L Rourke; Matthew C Ernst; Kerry B Goralski; Christopher J Sinal
Journal:  J Biol Chem       Date:  2011-05-14       Impact factor: 5.157

5.  Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}.

Authors:  Sebastian D Parlee; Matthew C Ernst; Shanmugam Muruganandan; Christopher J Sinal; Kerry B Goralski
Journal:  Endocrinology       Date:  2010-04-02       Impact factor: 4.736

6.  'Crommelin-type' symmetrical tetramelic reduction deformity: a new case and breakpoint mapping of a reported case with de-novo t(2;12)(p25.1;q23.3).

Authors:  Louise Harewood; Jean W Keeling; Judith A Fantes; John M Opitz; David R FitzPatrick
Journal:  Clin Dysmorphol       Date:  2010-01       Impact factor: 0.816

7.  Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes.

Authors:  Matthew C Ernst; Mark Issa; Kerry B Goralski; Christopher J Sinal
Journal:  Endocrinology       Date:  2010-03-12       Impact factor: 4.736

8.  Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice.

Authors:  T R Nagy; A L Clair
Journal:  Obes Res       Date:  2000-08

9.  Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells.

Authors:  Shanmugam Muruganandan; Alexandra A Roman; Christopher J Sinal
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

10.  Prostaglandin D2 inhibits C2C12 myogenesis.

Authors:  Pedro Veliça; Farhat L Khanim; Chris M Bunce
Journal:  Mol Cell Endocrinol       Date:  2010-01-28       Impact factor: 4.102

View more
  12 in total

1.  Effects of conditioned media from murine lung cancer cells and human tumor cells on cultured myotubes.

Authors:  Blas A Guigni; Jos van der Velden; C Matthew Kinsey; James A Carson; Michael J Toth
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-11-05       Impact factor: 4.310

Review 2.  Chemerin as an independent predictor of cardiovascular event risk.

Authors:  Sinan İnci; Gökhan Aksan; Pınar Doğan
Journal:  Ther Adv Endocrinol Metab       Date:  2016-02-08       Impact factor: 3.565

Review 3.  Chemerin regulation and role in host defense.

Authors:  Brian A Zabel; Mateusz Kwitniewski; Magdalena Banas; Katarzyna Zabieglo; Krzysztof Murzyn; Joanna Cichy
Journal:  Am J Clin Exp Immunol       Date:  2014-02-27

4.  Chemerin regulates formation and function of brown adipose tissue: Ablation results in increased insulin resistance with high fat challenge and aging.

Authors:  Yiqiang Zhang; Wen-Jun Shen; Shuo Qiu; Pinglin Yang; Garrett Dempsey; Lei Zhao; Qin Zhou; Xiao Hao; Dachuan Dong; Andreas Stahl; Fredric B Kraemer; Lawrence L Leung; John Morser
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.191

5.  MMP-2 is a novel histone H3 N-terminal protease necessary for myogenic gene activation.

Authors:  Judd C Rice; Benjamin H Weekley; Tomas Kanholm; Zhihui Chen; Sunyoung Lee; Daniel J Fernandez; Rachel Abrahamson; Alessandra Castaldi; Zea Borok; Brian D Dynlacht; Woojin An
Journal:  Epigenetics Chromatin       Date:  2021-05-17       Impact factor: 4.954

6.  A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease.

Authors:  Kareem L Graham; Jian V Zhang; Susanna Lewén; Thomas M Burke; Ton Dang; Maria Zoudilova; Raymond A Sobel; Eugene C Butcher; Brian A Zabel
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

7.  The expression and regulation of chemerin in the epidermis.

Authors:  Magdalena Banas; Aneta Zegar; Mateusz Kwitniewski; Katarzyna Zabieglo; Joanna Marczynska; Monika Kapinska-Mrowiecka; Melissa LaJevic; Brian A Zabel; Joanna Cichy
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

8.  Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia.

Authors:  Ralph Klose; Ewelina Krzywinska; Magali Castells; Dagmar Gotthardt; Eva Maria Putz; Chahrazade Kantari-Mimoun; Naima Chikdene; Anna-Katharina Meinecke; Katrin Schrödter; Iris Helfrich; Joachim Fandrey; Veronika Sexl; Christian Stockmann
Journal:  Nat Commun       Date:  2016-08-19       Impact factor: 14.919

Review 9.  International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function.

Authors:  Amanda J Kennedy; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2017-12-26       Impact factor: 25.468

10.  Elastase and tryptase govern TNFα-mediated production of active chemerin by adipocytes.

Authors:  Sebastian D Parlee; Jenna O McNeil; Shanmugam Muruganandan; Christopher J Sinal; Kerry B Goralski
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.